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Abstract 
The receptor activator of nuclear factor-κB ligand (RANKL) modulates energy metabolism. 
However, how RANKL regulates energy homeostasis is still not clear. This study aims to investigate 
the central mechanisms by which central administration of RANKL inhibits food intake and causes 
weight loss in mice. We carried out a systematic and in-depth analysis of the neuronal pathways by 
which RANKL mediates catabolic effects. After intracerebroventricle (i.c.v.) injection of RANKL, the 
expression of neuropeptide Y (NPY) mRNA in the Arc was significantly decreased, while the CART 
mRNA expression dramatically increased in the Arc and DMH. However, the agouti-related protein 
(AgRP) and pro-opiomelanocortin (POMC) mRNA had no significant changes compared with 
control groups. Together, the results suggest that central administration of RANKL reduces food 
intake and causes weight loss via modulating the hypothalamic NPY/CART pathways. 
Key words: Receptor activator of NF-κB ligand; Food intake; Cocaine- and amphetamine-regulated transcript; 
Neuropeptide Y; Hypothalamus 
Introduction 
About 500 million adults have developed obesity 
worldwide, which is associated with a greater risk of 
type II diabetes and cardiovascular disease that makes 
obesity as a major health, social and economic 
problems to most countries [1-3]. Various brain nuclei 
are involved in the control of body metabolisms, 
including insulin production and energy expenditure 
[4, 5]. Recent studies have proved a link between the 
central RANKL/RANK and energy homeostasis [6, 7]. 
RANKL is a 317-amino acid peptide that belongs to 
tumour necrosis factor (TNF) cytokine family [8]. Two 
forms of RANKL have been found, a 
membrane-bound molecule expressed on osteoblasts 
and a soluble form. RANKL plays an important role 
in bone reconstruction by binding and activating its 
receptor RANK, a 616-amino acid peptide [9, 10]. 
RANKL/RANK protein and mRNA are expressed in 
bone and bone marrow, lymphoid tissues [11], the 
hypothalamus and septal regions of the brain [6, 7]. 
Importantly, elevated levels of circulating soluble 
RANKL have been observed in the circulation of 
patients with anorexia nervosa compared to healthy, 
age-matched controls [12] and it is worth noting that 
RANKL levels depend on the severity of the anorexia 
nervosa [13]. Similarly, mice intraperitoneally injected 
with an adenovirus vector harbouring murine soluble 
RANKL cDNA exhibit reduced food intake and body 
weight [14]. Together, these findings support 
anorectic effects of RANKL. However, the precise 
hypothalamic nuclei and neuropeptides that mediate 
the effects of RANKL remain unexplored.   
Arcuate (Arc) and dorsomedial (DMH) nuclei in 
the hypothalamus are two main areas regulating 








interchange and integrate peripheral signals like 
calories intake, nutritional status to regulate appetite 
and energy expenditure [4, 15, 16]. Previous studies 
have shown a link between the DMH, ingestion and 
body weight regulation [17]. Lesion of the DMH 
results in hypophagia, reduced body weight and 
impaired growth in rats [18]. In the Arc, two types of 
neurons, NPY/agouti-related protein (AgRP) neurons 
and CART/pro-opiomelanocortin (POMC), are main 
functional units to produce orexigenic or anorexigenic 
neurotransmitters respectively [19, 20]. NPY is a 
36-amino acid peptide that drives body weight gain, 
increased food intake and decreased energy 
expenditure [4, 21, 22], while CART causes loss of 
appetite. Studies on bone remodelling reveal that 
RANKL signalling is modulated by CART and NPY. 
For instance, homozygous deletion of CART results in 
increased RANKL expression in bone and decreased 
bone mass [23], while NPY inhibits RANKL 
expression on osteoblasts [24]. However, the 
relationship among CART, NPY and RANKL in the 
regulation of energy balance remains to be addressed. 
A major goal of this study is to explore whether 
RANKL reduces food intake and causes body weight 
loss via modulating the hypothalamic NPY/CART 
neuronal pathways. 
Materials and Methods  
Ethical and animal care 
The experimental protocol was approved by the 
Third Military Medical University Animal Care 
Committee according to the National Institutes of 
Health Guide for the Care and Use of Laboratory 
Animals (NIH publication number 8023). All mice 
were housed under conditions of controlled 
temperature (22°C) and illumination (12-hour light 
cycle, lights on at 07:00 am) with ad libitum access to 
water and normal chow (6% calories from fat, 21% 
calories from protein, 71% calories from carbohydrate, 
Gordon’s Specialty Stock Feeds, Australia) unless 
otherwise stated. 
Body weight, food intake measurement 
Eleven C57BL/6J male mice were divided into 
two groups, treated with either RANKL 
(intracerebroventricle, i.c.v. injection, n=6) or saline as 
control group (n=5). After three days of 
acclimatization, we implanted ALZET® 
Micro-Osmotic Pump (LOT NO. 10239-10, Model 
1007D, Flow rate 0.5μl/hour) in mice for RANKL i.c.v. 
injection which contained RANKL (7 days) and 
allowed for a constant stream of 10 ng per day 
RANKL to be delivered directly into the third 
ventricle of brain. The procedure of the 
Micro-Osmotic Pump implantation was performed as 
described in previous study [25]. Meanwhile, we 
applied the same surgery to the other group, in which 
pump contained saline as controls. The subsequent 
measurement of body weight was taken daily at the 
same time. At the 8th day, cumulative food intake in 24 
hours (from 7th day 10:00 to 8th day 10:00) of two 
groups was calculated separately. Both groups of 
mice were used for the detection of in situ 
hybridization mRNA expression. 
Immunohistologic analysis of RANKL altered 
c-fos expression in brain  
At the age of 16 weeks, ten C57BL/6J male mice 
were divided into two groups: one group of mice for 
RANKL i.v. injection (n=5) and the other group of 
mice for saline i.v. injection as controls (n=5), and both 
groups were used for c-fos detection. The mice were 
i.v. injected with 10 µg RANKL diluted in 1ml saline 
or 1ml saline for 30 min and then deeply anesthetized 
with ketamine-xylazine (100 mg / kg and 20 mg / kg 
from Parke Davis Pfizer, Sydney, Australia and Bayer 
AG, Leverkusen, Germany, respectively) through 
intraperitoneally injection. From the left heart 
ventricle, 25ml of phosphate buffered saline (PBS) and 
4% paraformaldehyde dissolved in PBS were 
perfused into the whole body successively. After 
dislocating and sacrificing the mice, we removed the 
brain immediately, then placed it in 4% 
paraformaldehyde PBS solution for 30 minutes and 
transferred to 30% sucrose solution to remain 
overnight and restored in -70 °C refrigerator. 30 mm 
thickness of coronal slices were placed in PBS and 
washed in 50% ethanol which contained 1% H2O2 for 
20 minutes to abolish endogenous peroxidase activity. 
Brain section was incubated with the primary 
antibody, rabbit anti-mouse c-fos protein (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA) which was 
diluted at 1: 4000 in PBS containing 0.1% TRITON 
X-100, at room temperature overnight. After washing 
in 0.1% TRITON X-100-PBS for 10 minutes and 
repeated three times, sections were incubated for 3 
hours with the biotinylated secondary antibody 
(Sigma-Aldrich, St Louis, MO, USA), diluted at 1:250 
in PBS. Again, washing in PBS for 10 minutes 3 times, 
brain sections were incubated with Avidin 
Biotin-Peroxidase VectastainH (Vector Laboratories, 
Burlingame, CA, USA) at room temperature for 30 
minutes. Then sections were rinsed in PBS and treated 
with diaminobenzidine (Dako, Carpinteria, CA, USA) 
for 5 minutes. Finally, sections were rinsed with 
water, mounted on slides, and dehydrated before 
cover slipping. Sections were visualized for c-fos-like 
immunoreactivity by using a Zeiss Axiophot 
microscope equipped with the Prog Res digital 




camera (Carl Zeiss Imaging Solutions GmbH, Munich, 
Germany). Semiquantitative analysis of c-fos has been 
described previously [4]. 
Double labelling of c-fos and NPY 
In order to verify whether NPY neurons in the 
hypothalamus are involved in response to RANKL i.v. 
injection, double-labelling experiment was performed 
to ascertain whether NPY neurons were activated by 
RANKL i.v. injection. At the age of 16 weeks, eight 
transgenic NPY Green Fluorescent Protein (GFP) male 
mice expressing green fluorescent protein (purchased 
from Jackson Laboratory) were divided into two 
groups: one group of mice for RANKL i.v. injection 
(n=4) and the other group of mice for saline i.v. 
injection as controls (n=4), and both group of mice 
were used for c-fos detection. These NPYGFP mice 
were i.v. injected with 10 µg RANKL diluted in 1 ml 
saline or 1 ml saline for 30 min and then sacrificed 
after deeply anaesthetized. Following steps were 
carried out as c-fos immunohistochemistry test stated 
above. Brain section was incubated with the primary 
antibody, rabbit anti-mouse c-fos protein (Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA) diluted at 
1:4000. The secondary antibody against c-fos 
visualizing red fluorescent was Alexa Fluor 594 goat 
anti-rabbit IgG (A11037, Life Technologies, Canada) 
diluted at 1:250. Sections were mounted with 
fluoromount and quantified for c-fos immunoreac-
tivity in NPY-GFP transgenic mice using a ProgRes 
3008 camera (Zeiss, Jena, Germany). 
Double labelling of c-fos and CART mRNA  
In order to determine whether CART neurons in 
the hypothalamus are activated by RANKL i.v. 
injection, four C57BL/6J male mice, sixteen week old, 
were i.v. injected with 10 µg RANKL diluted in 1ml 
saline, and another four mice were i.v. injected with 
1ml saline as controls. At 30 min after treatment, mice 
were deeply anaesthetised, and the brains were fixed 
by perfused with 25ml phosphate buffered saline 
(PBS) and 4% paraformaldehyde dissolved in PBS. 
After soaking in 30% sucrose solution overnight, the 
brain was cut into coronal sections of 30μm thickness. 
Immunoreactivities of c-fos were carried out as stated 
above. Brain sections were incubated with secondary 
antibodies, goat anti-rabbit (Sigma-Aldrich, St Louis, 
MO, USA), for three hours, which was diluted at 1:250 
in PBS. Sections were mounted and CART in situ 
hybridisation was performed as previously described 
[26]. DNA oligonucleotides complementary to mouse 
CART (5’-TCCTTCTCGTGGGACGCATCATCCACG 
GCAGAGTAGATGTCC AGG-3’) was labelled with 
[35S] thio-dATP. Co-localization of c-fos and CART 
mRNA were captured and counted under a Zeiss 
Axiophot microscope. 
In Situ Hybridization for Quantification of NPY, 
CART, POMC and AgRP mRNA Expression 
At the 8th day, all mice treated with RANKL (n=6) 
or saline (n=5) from implanted micro-osmotic pump 
were deeply anesthetized with ketamine-xylazine 
(100 mg / kg and 20 mg / kg from Parke Davis Pfizer, 
Sydney, Australia and Bayer AG, Leverkusen, 
Germany, respectively) through intraperitoneal 
injection. After sacrificing mice with the same 
procedure stated above, we cut 20μm coronal slices 
and prepared them as described in previous study 
[26, 27]. For radioactive in situ hybridization, DNA 
oligonucleotides complementary to mouse NPY 
(5’-GAGGGTCAGTCCACACAGCCCCATTCGCTTG
TTACCTAGCAT-3’) CART (5’-TCCTTCTCGTGGGA 
CGCATCATCCACGGCAGAGTAGATGTCCA 
GG-3’), POMC (5’-TGGCTGCTCTCCAGGCACCAG 
CTCCACACATCTATGGAG G-3’), or AgRP (5’-AGC 
TTGCGGCAGTAGCAAAAGGCATTGAAGAAGCG
GCA GTAGCAC-3’) were labelled with [35S] 
thio-dATP (Amersham Biosciences, Little Chalfont, 
Buckinghamshire, UK) using terminal deoxynucleo-
tidyl transferase (Roche, Mannheim, Germany). The 
mRNA levels of NPY, CART, POMC and AgRP in the 
Arc, and CART in the DMH were evaluated, 
respectively, by measuring silver grain densities over 
individual neurons from photo-emulsion dipped 
sections, as described previously [4, 26].  
Statistical analysis 
All statistical analyses were performed using 
GraphPad Prism Version 6.0 (GraphPad Software, 
Inc). Differences between means were assessed, as 
appropriate, by two- or one-way ANOVA followed 
by Bonferroni post hoc analysis. For all statistical 
analyses, a P value <0.05 was considered to be 
statistically significant. Data were presented as means 
± SEM. 
Results 
Body weight and food intake in response to 
RANKL administration  
During 7 days of treatment, the mice treated 
with RANKL displayed a significant reduction of 
body weight compared with controls (Fig. 1A). 
Average food intake of each mouse in 24 hours 
measured at day 8th showed that the mice treated with 
RANKL had lower food intake compared with 
controls, which demonstrated that the administration 
of central RANKL inhibited food intake (Fig. 1B). 





Figure 1. The body weight and food intake of mice altered after RANKL 
injection. Quantifications of body weight and food intake. Data are mean ± SEM. n=6 
in RANKL group, n=5 in Saline group ** p<0.001 compared with Saline group. 
*p<0.05 compared with Saline group. 
 
Activated c-fos immunoreactive neurons in 
hypothalamus after RANKL administration  
To clarify which regions of hypothalamus have 
been influenced by i.v injection of RANKL, we 
examined c-fos immunohistochemistry (Fig. 2). The 
c-fos, a proto-oncogene which is referred to as an 
immediate early gene for c-fos mRNA and protein, is 
generally among the first to be expressed. We 
observed that there were significantly more marked 
neurons in the section of RANKL treated group than 
control group in the Arc (Fig. 2A-C) and DMH (Fig. 
2D-F) regions. The elevated expression of c-fos 
suggested that neurons in these regions were 
activated by RANKL, and revealed that RANKL 
might induce changes in NPY and its downstream 
signalling pathways.  
NPY and CART mRNA co-localised with c-fos 
neurons  
Considering that administration of peripheral 
RANKL triggered more expression of c-fos gene in the 
Arc and DMH, we detected some neuropeptide genes 
that regulated energy homeostasis to show which 
genes were activated on neurons labelled by c-fos 
after i.v injection of RANKL. In the Arc, we found 
significant 54% overlap in expression of NPYGFP 
neurons (Fig. 3B) and c-fos (Fig. 3A) at 30 min after i.v. 
administration of RANKL (Table. 1) (Fig. 3C), which 
suggested that NPY-producing cells may be involved 
in mediating RANKL-induced decreased appetite and 
changes in energy intake. In addition, the 
double-labelling method combining c-fos 
immunohistochemistry with in situ hybridization 
showed that about 72% neurons expressed c-fos 
immunoreaction and CART mRNA in the DMH 
(Table. 1) (Fig. 4A-B). The expression of CART mRNA 
at 30 min after i.v injection of RANKL indicated that 
DMH CART neurons were also critical in mediating 
anorectic effect of RANKL. 
 
 
Figure 2. Activated c-fos immunoreactive neurons in the Arc and DMH after RANKL administration. A-F. Immunohistochemical analysis of c-fos expression in 
the Arc and DMH after i.v administration of RANKL or saline. The c-fos positive neurons were sharply increased in the Arc (A-C) and DMH (D-F) of RANKL peripheral injection. 
Scale bar 100μm. Quantification of c-fos neurons expressed in the Arc and DMH. Data are mean ± SEM of 5 mice each group. *** p<0.001 vs Saline controls. 3V: the third 
cerebral ventricle. Arc: Arcuate nucleus. 






Figure 3. NPY co-localised with c-fos neurons in response to RANKL i.v injection. Fluorescent immunohistochemical identification of c-fos and NPY GFP neurons 
co-expressed in the Arc, 30 min after RANKL i.v injection. Red staining showed c-fos positive neurons only (A), with green staining indicating NPY neurons expressing GFP (B), 
and yellow staining indicating the neurons expressing both c-fos and NPY (C). Scale bar 40μm. (D) Boxed area shown in high-magnification. 3V: the third cerebral ventricle. 
 
Figure 4. CART mRNA co-localised with c-fos neurons in the DMH after i.v. injection of RANKL. Double labeling of in situ hybridization for CART mRNA and 
immunohistochemistry for c-fos expression in the DMH, 30 min after i.v. injection of RANKL. A: low-magnification. B: boxed area shown in high-magnification. Black arrows 
indicate CART mRNA and red arrows indicate double-labelled c-fos and CART mRNA. 3V: the third ventricle. Scale bar: B=5μm. 
 
Table 1. NPY and CART mRNA co-localised with c-fos neurons 
 GFP-positive cells GFP-positive cells expressing c-fos % GFP-positive cells expressing c-fos 
NPY-GFP mice (n=4) 89.1±4.2 47.8±3.7 54.5±6.7 
 c-fos positive cells c-fos positive cells expressing CART mRNA %c-fos positive cells expressing CART mRNA 
C57BL/6J mice (n=4) 42.5±4.7 30.3±3.5 72.5±6.5 
Data represent mean ± SEM. 
 
The expression of NPY, CART, POMC and 
AgRP mRNAs in response to central 
administration of RANKL  
Through c-fos immunoreactivity test, we 
elucidated that the Arc and DMH were influenced by 
RANKL. Given that both the regions are closely 
related to energy homeostasis, we detected the 
expression of several neurotransmitters which 
modulated energy metabolism through in situ 
hybridization. Compared with control group, RANKL 
treated group displayed significant decreased 
expression of NPY mRNA in the Arc (Fig. 5A-C), 
whereas the expression of CART mRNA in the Arc of 
RANKL treated group was significantly increased 
(Fig. 5D-F). In addition, no significant changes of 
POMC mRNA were detected (Fig. 6A-C), even 
though POMC was co-expressed with CART [28]. As 
we know, AgRP is co-expressed with NPY and 
capable of increasing appetite and decreasing 
metabolism and energy expenditure, but there was no 
significant decrease of AgRP mRNA expression in the 
Arc of RANKL treated group compared with control 
group (Fig. 6D-F). In the DMH, there was 
up-regulation of CART mRNA expression in RANKL 
group (Fig. 7A-C). These experiments revealed that 
the central injection of RANKL may modulate the 
expression of NPY mRNA in the Arc and CART 
mRNA in the Arc and DMH to inhibit food intake and 
reduce body weight. 






Figure 5. The RANKL influenced the expression of NPY mRNA and CART mRNA in the Arc. Bright filed micrographs of in situ hybridisation showed NPY mRNA 
in the Arc, 7 days after i.c.v. injection of RANKL (A) or saline (B). Quantification of NPY mRNA expressed in the Arc comparing to saline mice (C). Bright filed micrographs of 
in situ hybridisation showed CART mRNA in the DMH, 7 days after i.c.v. injection of RANKL (D) or saline (E). Quantification of CART mRNA expressed in the Arc comparing 
to saline mice (F). Scale bar 200μm. Data were mean ± SEM of 5 - 6 mice each group. *** p<0.001 vs Saline controls,* p<0.05 vs. Saline controls. 3V: the third ventricle. Arc: 
Arcuate nucleus 
 
Figure 6. The RANKL did not affect POMC mRNA and AgRP mRNA expression in the Arc. Bright filed micrographs of in situ hybridisation showed POMC mRNA 
in the Arc, 7 days after i.c.v. injection of RANKL (A) or saline (B). Scale bar 200μm. Quantification of POMC mRNA expressed in the Arc as a percent of saline mice (C). Bright 
filed micrographs of in situ hybridisation showed AgRP mRNA in the Arc, 7 days after i.c.v. injection of RANKL (D) or saline (E). Scale bar 200μm. Quantification of CART mRNA 
expressing in the Arc as a percent of saline mice (F). Data were mean ± SEM of 5 - 6 mice each group. 3V: the third ventricle. Arc: Arcuate nucleus 
 
Figure 7. The RANKL influenced the expression of CART mRNA in the DMH. Bright filed micrographs of in situ hybridisation showed CART mRNA in the DMH, 7 
days after i.v. injection of RANKL (A) or saline (B). Scale bar 100μm. Quantification of CART mRNA expressed in the DMH as a percent of saline mice (C). Data are mean ± SEM 
of 5 - 6 mice each group. *** p<0.001 vs Saline controls,* p<0.05 vs Saline controls. 3V: the third ventricle. 






 Obesity is a chronic metabolic disease, 
attributing to various factors, such as genetic factors, 
unhealthy eating patterns, or a combination of these 
factors [16]. The main pathogenesis of obesity is 
energy metabolic imbalance and weight regulation 
disorder. Many neurotransmitters in the 
hypothalamus have been implicated in the regulation 
of energy homeostasis and weight regulation [4, 21, 
22, 29-31]. In our research, we verified whether NPY, 
CART, POMC and AGRP were involved in the 
catabolic effects via RANKL signal pathway. 
 RANKL, an acid peptide which can pass 
through the blood brain barrier [32] and binds to 
RANK expressed in the hypothalamus. RANKL 
treatment significantly inhibited daily food intake 
compared with control group, implying that 
administration of peripheral RANKL led to altered 
feeding behaviour. C-fos, a proto-oncogene which is 
referred to as an immediate early gene for c-fos 
mRNA and protein, is generally among the first to be 
expressed after specific stimulation. We identified 
changes in hypothalamic c-fos expression in response 
to peripheral RANKL administration. The present 
study showed there was altered expression of c-fos 
compared with controls. After i.v. RANKL 
administration, particularly strong increases in c-fos 
expression were noted in the Arc and DMH. This 
suggested that these neurons activated by RANKL 
may play an important role in inhibiting food intake 
and decreasing the body weight of mice.  
 NPY/AgRP neurons in the Arc, modulate 
energy homeostasis by promoting food intake and 
reducing energy expenditure [22]. Some circulating 
hormones and metabolic mediators, such as leptin 
and RANKL [33], can across the blood brain barrier to 
reach NPY/AgRP neurons in the Arc. Food 
deprivation can sharply elevate the NPY levels in the 
Arc, which is capable of correcting negative energy 
balance [4, 34]. I.c.v. delivery of NPY leads to robust 
hyperphagia and the development of morbid obesity 
[35], indicating that the NPY not only regulates 
feeding but also controls energy storage. In current 
study, after peripheral treatment of RANKL, there 
was significant overlap in expression of Arc NPY and 
c-fos labelled neurons in NPY GFP mice. In situ 
hybridisation showed a down-regulation of NPY 
mRNA after i.c.v. injection of RANKL. The levels of 
AgRP mRNA in the Arc remained unchanged in 
RANKL treated group comparing to saline injection 
group. All results suggested that reduced NPY 
diminished appetite, which could be a possible reason 
to weight loss of mice after administration of RANKL. 
As we know, CART is an orexigenic 
neurotransmitter produced by POMC/CART neurons 
in the Arc. It also reduces body weight by inhibiting 
food intake and increasing energy expenditure. 
Fasting down-regulates CART mRNA in the Arc, 
PVN and PeF [19]. Moreover, delivery of CART 
strongly curbed both spontaneous and fasting- 
induced food intake [36]. In this study, we used 
double-labelling techniques to determine the chemical 
nature of neurons activated within hypothalamic 
areas which were associated with energy metabolism 
[37]. Approximately 72% of c-fos neurons in the DMH 
were co-localised with CART mRNA after treatment 
of RANKL, indicating that DMH CART neurons were 
also critical in mediating anorectic effect of RANKL. 
The results from in situ hybridisation showed 
up-regulation of CART mRNA in the Arc and the 
DMH after i.c.v. injection of RANKL, and the 
expression of POMC mRNA remained almost the 
same in two groups. It was possible that 
administration of RANKL induced the production of 
CART, which subsequently led to weight loss.  
 Furthermore, CART and NPY are reciprocally 
regulated. NPY-stimulated feeding is blocked by 
administration of CART [36, 38]. It has been 
elucidated that Arc NPY neurons project to the DMH, 
which influences the energy homeostasis [39-41]. In 
the DMH, the neurons expressing NPY have been 
found to co-express CART [42]. Moreover, NPY/ 
AgRP neurons can directly inhibit CART/POMC 
neurons either by NPY-Y receptor activation or 
release of GABA [43]. Our findings also indicate that 
CART in the DMH is the downstream of NPY, which 
is consistent with previous evidence [21]. Thus, 
decreased Arc NPY may lead to upregulation of 
CART in the DMH. In addition, after treatment of 
RANKL to mice, NPY mRNA was decreased and 
CART mRNA was increased in the Arc. As two sets of 
neurons present reciprocal metabolic effects, the 
changes of mRNA in both neurons result in inhibitory 
food intake. Moreover, as the downstream of NPY, 
increased CART in the DMH was regulated either by 
NPY or by RANKL directly. All these findings 
elucidate the possibility that RANKL has anti-obesity 
effects.  
 In summary, the primary outcomes of this study 
have provided a new understanding about the 
neuronal mechanisms underlying the effects of 
RANKL on food intake and energy homeostasis, 
which is mediated by the hypothalamic NPY-CART 
pathway. These results may provide a platform to 
identify new drug targets for the development of 
suitable pharmacological treatments for obesity. 
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